- Consumer Products
- Latest 10.54
- Currency US$
- Change -0.69
- Percent Change -6.144 %
- Volume 740,361
- Wed Dec 11, 2013 04:00 PM EST NASDAQ data delayed 15 minutes.
12 months ended Sep 30, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Nov 7||$-0.19||Feb 27||$-0.16|
12 months ended Dec 11, 2013.
A look at major corporate events and financial announcements that are coming up.
About the Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.